Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay

Inclusion Criteria: * The subject is chronically infected with HBV.The subject is treatment naïve and is initiating HBV antiviral therapy with either entecavir or tenofovir as indicated in the FDA approved label * The subject will be considered treatment naïve if he/she had \<12 weeks of oral antiviral therapy with any nucleoside or nucleotide therapy * The subject is at least 18 years of age at the time of enrollment * Adequate medical records are available for collection of protocol-defined demographics, baseline patient characteristics, medical history, virology and specific laboratory results, and other information to verify enrollment criteria * The subject and/or legally authorized representative is willing and able to provide consent prior to providing a specimen(s) Exclusion Criteria: * Subject is in one of the following patient populations: * Acute HBV infection * Patients who are HBV immune tolerant * Human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV) co-infection * Solid organ or bone marrow transplant recipients * Renal failure or dialysis * Evidence or history of hepatic decompensation * Evidence or history of hepatocellular carcinoma * Underlying liver disease other than HBV * Receiving chemotherapy, immunosuppressive agents * Subject is unsuitable for study participation based on the Investigator's decision (eg, unlikely to comply with study visit schedule, significant medical complication) * Participating in another investigational study that the Investigator believes might interfere with the subject's participation in this study